株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:多発性硬化症

Medical Affairs Reputations: Multiple Sclerosis (EU5) 2017

発行 FirstWord 商品コード 520355
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
EU5カ国におけるMA (メディカルアフェアーズ) 部門の評価:多発性硬化症 Medical Affairs Reputations: Multiple Sclerosis (EU5) 2017
出版日: 2017年06月01日 ページ情報: 英文
概要

当レポートでは、多発性硬化症治療薬の主要10製品を取り扱う各社メディカルアフェアーズ (MA) チームについてEU5カ国の神経科医150名を対象に調査し、各社チームのパフォーマンスおよび満足度に対するスコアリングおよびランキング、医師によるサービス利用の動向、要望、改善箇所などの分析をまとめています。

対象の企業・ブランド

  • Aubagio (テリフルノミド:Sanofi)
  • Avonex (インターフェロンβ1a:Biogen)
  • Betaferon (インターフェロンβ1b:Bayer)
  • Copaxone (グラチラマー酢酸塩:Teva)
  • Gilenya (フィンゴリモド:Novartis)
  • Lemtrada (アレムツズマブ:Sanofi)
  • Plegridy (ペグインターフェロンβ1a:Biogen)
  • Rebif (インターフェロンβ1a:Merck KGaA)
  • Tecfidera (フマル酸ジメチル:Biogen)
  • Tysabri (ナタリズマブ:Biogen)

調査・分析内容の例

  • 医師のニーズ
    • 医師によるMAチームの利用方法・頻度
    • もっとも重要と考えるサービス
    • 最適なコンタクトの頻度と経路
  • MAチームの提供する内容
    • 医師によるチームとのインタラクションの印象
    • 医師によるチームのパフォーマンス・満足度ランキング:12項目
    • 他のチームとの比較
  • 改善が必要な箇所、など
目次

Winners and losers: How well is your MS medical affairs team doing?

Which MS drugs are benefiting from the best performing and most supportive medical affairs teams according to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but almost a quarter of physicians suggest that medical affairs teams could improve their attitude and practice. Is 'satisfactory' good enough? If not, what more could be done to build stronger relationships?

Use this latest report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS EU5) features 10 leading MS drugs from Biogen, Sanofi, Bayer, Novartis, Merck KGaA and Teva.

Find out what more doctors want from your medical affairs team including:

  • Which services are most important?
  • Preferred contact methods and frequency
  • Areas for improvement

Top Takeaways

  • Busy, busy: For most drugs, the majority of physicians surveyed recall hearing from medical affairs in the last six months. Which medical affairs teams get full marks for effort?
  • To see, or not to see? Plenty of MS doctors want face-to-face meetings, but the majority also cite two other communication channels they'd appreciate.
  • More information please: Nearly a third of physicians want to know more from medical affairs - more detail, more updates, more relevance.
  • One medical affairs team is streets ahead: One team sits in the top three for satisfaction for every single attribute - a phenomenal performance. Is this your medical affairs team, or a competitor's?

Insight into 10 MS Drugs

  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaferon (interferon beta-1b; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Sanofi)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; Merck KGaA)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)

A Competitive Assessment of Medical Affairs Teams

Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions such as:

What do doctors need?

  • How, and how often are doctors using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Expert Knowledge

We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain and the UK).

All respondents:

  • Have been practising for 3+ years
  • See at least 5 MS patients in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted in the last 6 months with a medical affairs professional for at least one of the listed products.

We conducted the survey between 2nd and 9th May 2017.

Back to Top